Relmada Therapeutics, Inc.
RLMD
$4.18
$0.143.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.01% | 18.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.04% | -43.90% | |||
| Operating Income | -1.04% | 43.90% | |||
| Income Before Tax | -2.28% | 43.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.28% | 43.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | 43.81% | |||
| EBIT | -1.04% | 43.90% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.25% | 48.51% | |||
| Normalized Basic EPS | -1.82% | 48.99% | |||
| EPS Diluted | -2.25% | 48.51% | |||
| Normalized Diluted EPS | -1.82% | 48.99% | |||
| Average Basic Shares Outstanding | 0.00% | 9.15% | |||
| Average Diluted Shares Outstanding | 0.00% | 9.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||